Compare BioNTech SE - ADR (BNTX) vs VanEck Gold Miners ETF (GDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNTech SE - ADR vs VanEck Gold Miners ETF — how do they compare? BioNTech SE - ADR trades at $89.89 (market cap $22.86B), while VanEck Gold Miners ETF trades at $73.94. The key difference: VanEck Gold Miners ETF is trading nearer its 52-week high, BioNTech SE - ADR nearer its low. Which is the better fit depends on your goals.
| BNTX | GDX | |
|---|---|---|
Market Cap | $22.86B | — |
Sector | Health | — |
52-Week High | $119.34 | $115.84 |
52-Week Low | $83.89 | $51.15 |
Enterprise Value | $6.53B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BioNTech (BNTX) trades at $90.07, down 1.55% today, amid a bearish technical signal and declining revenue trends. The company reported a net loss of $1.14 billion in 2025, with profitability metrics negative, though it maintains a strong cash position of $16.78 billion. Recent news highlights restructuring efforts, including site closures and a $1 billion share buyback, as it pivots focus to oncology pipeline development following reduced COVID-19 vaccine demand.
The outlook remains challenging with persistent losses and competitive pressures, but analyst consensus is bullish with a $129.67 price target. Key risks include execution of the oncology strategy and revenue volatility. The stock's current valuation reflects uncertainty, offering potential upside if pipeline milestones are met, but investors face significant operational and market headwinds.
GDX, the VanEck Gold Miners ETF, trades at $73.37, down 2.86% in the last 24 hours amid a bearish technical signal from moving averages. The fund's valuation metrics are not available, but recent news highlights competition from lower-fee gold ETFs and a recent addition of Aya Gold & Silver to its holdings. Technical indicators show neutral oscillators with key support at $71 and resistance at $74.
The outlook for GDX is cautious due to underperformance versus physical gold and higher volatility. Investment opportunities lie in potential gold price rebounds and record-high free cash flow yields, but risks include fee disadvantages and sector-specific volatility. Analyst sentiment is mixed, with some seeing a buying opportunity amid low valuations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BioNTech SE - ADR
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies.
Read more on BNTX →About VanEck Gold Miners ETF
The fund normally invests at least 80% of its total assets in common stocks and depositary receipts of companies involved in the gold mining industry. The index is a modified market-capitalization weighted index primarily comprised of publicly traded companies involved in the mining for gold and silver. The fund is non-diversified.
Read more on GDX →
